Michel Koole1, Donatienne Van Weehaeghe1,2, Kim Serdons2, Marissa Herbots3, Christopher Cawthorne1, Sofie Celen4, Frederick A Schroeder5, Jacob M Hooker6, Guy Bormans4, Jan de Hoon3, Janice E Kranz5, Koen Van Laere1,2, Tonya M Gilbert7. 1. Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000, Leuven, Belgium. 2. Nuclear Medicine and Molecular Imaging, University Hospitals Leuven, 3000, Leuven, Belgium. 3. Center for Clinical Pharmacology, University Hospitals Leuven, 3000, Leuven, Belgium. 4. Laboratory for Radiopharmaceutical Research, KU Leuven, 3000, Leuven, Belgium. 5. Eikonizo Therapeutics, Inc., LabCentral, 700 Main Street North, Cambridge, MA, 02139, USA. 6. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA. 7. Eikonizo Therapeutics, Inc., LabCentral, 700 Main Street North, Cambridge, MA, 02139, USA. tonya.gilbert@eikonizo.com.
Abstract
PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer's disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [18F]EKZ-001 ([18F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (VT) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. VT differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA VT were in agreement with 2TCM VT, however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional VT values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher VT than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [18F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females.
PURPOSE: Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that modulates intracellular transport and protein quality control. Inhibition of HDAC6 deacetylase activity has shown beneficial effects in disease models, including Alzheimer's disease and amyotrophic lateral sclerosis. This first-in-human positron emission tomography (PET) study evaluated the brain binding of [18F]EKZ-001 ([18F]Bavarostat), a radiotracer selective for HDAC6, in healthy adult subjects. METHODS: Biodistribution and radiation dosimetry studies were performed in four healthy subjects (2M/2F, 23.5 ± 2.4 years) using sequential whole-body PET/CT. The most appropriate kinetic model to quantify brain uptake was determined in 12 healthy subjects (6M/6F, 57.6 ± 3.7 years) from 120-min dynamic PET/MR scans using a radiometabolite-corrected arterial plasma input function. Four subjects underwent retest scans (2M/2F, 57.3 ± 5.6 years) with a 1-day interscan interval to determine test-retest variability (TRV). Regional volume of distribution (VT) was calculated using one-tissue and two-tissue compartment models (1-2TCM) and Logan graphical analysis (LGA), with time-stability assessed. VT differences between males and females were evaluated using volume of interest and whole-brain voxel-wise approaches. RESULTS: The effective dose was 39.1 ± 7.0 μSv/MBq. Based on the Akaike information criterion, 2TCM was the preferred model compared to 1TCM. Regional LGA VT were in agreement with 2TCM VT, however demonstrated a lower absolute TRV of 7.7 ± 4.9%. Regional VT values were relatively homogeneous with highest values in the hippocampus and entorhinal cortex. Reduction of acquisition time was achieved with a 0 to 60-min scan followed by a 90 to 120-min scan. Males demonstrated significantly higher VT than females in the majority of cortical and subcortical brain regions. No relevant radiotracer related adverse events were reported. CONCLUSION: [18F]EKZ-001 is safe and appropriate for quantifying HDAC6 expression in the human brain with Logan graphical analysis as the preferred quantitative approach. Males showed higher HDAC6 expression across the brain compared to females.
Authors: Jim P Dompierre; Juliette D Godin; Bénédicte C Charrin; Fabrice P Cordelières; Stephen J King; Sandrine Humbert; Frédéric Saudou Journal: J Neurosci Date: 2007-03-28 Impact factor: 6.167
Authors: Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén Journal: Science Date: 2015-01-23 Impact factor: 47.728
Authors: Hsiao-Ying Wey; Tonya M Gilbert; Nicole R Zürcher; Angela She; Anisha Bhanot; Brendan D Taillon; Fredrick A Schroeder; Changing Wang; Stephen J Haggarty; Jacob M Hooker Journal: Sci Transl Med Date: 2016-08-10 Impact factor: 17.956
Authors: Paris R Watson; Ping Bai; Changning Wang; Abigail D Cragin; Jacob M Hooker; David W Christianson Journal: Biochemistry Date: 2022-09-08 Impact factor: 3.321
Authors: Silvio Aime; Mohammed Al-Qahtani; Martin Behe; Guy Bormans; Giuseppe Carlucci; Jean N DaSilva; Clemens Decristoforo; Adriano Duatti; Philip H Elsinga; Klaus Kopka; Xiang-Guo Li; Zhibo Liu; Robert H Mach; Oskar Middel; Jan Passchier; Marianne Patt; Ivan Penuelas; Ana Rey; Peter J H Scott; Sergio Todde; Jun Toyohara; Danielle Vugts; Zhi Yang Journal: EJNMMI Radiopharm Chem Date: 2021-03-18
Authors: Ping Bai; Prasenjit Mondal; Frederick A Bagdasarian; Nisha Rani; Yan Liu; Ashley Gomm; Darcy R Tocci; Se Hoon Choi; Hsiao-Ying Wey; Rudolph E Tanzi; Can Zhang; Changning Wang Journal: Acta Pharm Sin B Date: 2022-05-20 Impact factor: 14.903